SUPRIYA

1. Strong focus on API business Supriya Lifescience continues to strengthen its position in the Active Pharmaceutical Ingredients (API) segment. The company supplies APIs to domestic as well as international pharmaceutical companies. 2. Export business remains a major growth driver A significant portion of revenue comes from exports across regulated and semi-regulated markets. Expansion in international markets continues to support long-term growth prospects. 3. Capacity expansion initiatives The company is investing in expanding manufacturing capacities to meet growing demand and support future product launches. New facilities are expected to enhance production capabilities and operational efficiency. 4. Product portfolio diversification Supriya Lifescience is focusing on expanding its portfolio of APIs across therapeutic categories. New product introductions are aimed at reducing dependence on a limited set of products. 5. Beneficiary of China+1 strategy Global pharmaceutical companies continue diversifying sourcing away from China. This trend is creating opportunities for Indian API manufacturers like Supriya Lifescience. 6. Margin trends under watch Investors are closely tracking raw material costs, pricing trends and operating margins. The company continues focusing on cost optimization and efficiency improvements. 7. Strong balance sheet Supriya Lifescience maintains a relatively healthy financial position with manageable debt levels and stable cash generation. 8. Regulatory compliance remains important The company continues investing in quality standards and regulatory compliance to support growth in export markets. 9. Key growth triggers investors are watching Major factors being tracked include: New API launches Capacity utilization Export growth Margin improvement Expansion into regulated markets